Heart failure with preserved ejection fraction - coming to terms with an oxymoron

Editorial

Peter S Macdonald. Med J Aust. 2010.

. 2010 Jan 4;192(1):4-5.

doi: 10.5694/j.1326-5377.2010.tb03390.x.

No abstract available

Comment on

Current controversies in heart failure with a preserved ejection fraction.
MacIver DH. MacIver DH. Future Cardiol. 2010 Jan;6(1):97-111. doi: 10.2217/fca.09.56. Future Cardiol. 2010. PMID: 20014990 Review.
[Prognostic impact of heart failure with preserved versus reduced ejection fraction in patients with mild symptoms].
Jung P, Huber T, Müller M, König A, Krötz F, Sohn HY. Jung P, et al. Dtsch Med Wochenschr. 2012 Apr;137(14):706-10. doi: 10.1055/s-0031-1299011. Epub 2012 Mar 27. Dtsch Med Wochenschr. 2012. PMID: 22454198 German.
Wall stress determines systolic and diastolic function--Characteristics of heart failure.
Alter P, Koczulla AR, Nell C, Figiel JH, Vogelmeier CF, Rominger MB. Alter P, et al. Int J Cardiol. 2016 Jan 1;202:685-93. doi: 10.1016/j.ijcard.2015.09.032. Epub 2015 Sep 25. Int J Cardiol. 2016. PMID: 26454537 Clinical Trial.
Empagliflozin (Jardiance) for heart failure with reduced ejection fraction.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2021 Nov 1;63(1636):171-172. Med Lett Drugs Ther. 2021. PMID: 35085205 No abstract available.
Causes and pathophysiology of heart failure with preserved ejection fraction.
Kovács Á, Papp Z, Nagy L. Kovács Á, et al. Heart Fail Clin. 2014 Jul;10(3):389-98. doi: 10.1016/j.hfc.2014.04.002. Epub 2014 May 22. Heart Fail Clin. 2014. PMID: 24975903 Review.